Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Kai-Xuan Liu, Jian-Guo Hong, Rui Wu, Zhao-Ru Dong, Ya-Fei Yang, Yu-Chuan Yan, Chun-Cheng Yang, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Xu-Ting Zhi and Tao Li*

Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China

Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.

Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMan for data analysis and completed the study under the PRISMA guidelines.

Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.

Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.

Keywords: hepatocellular carcinoma, HBV reactivation, antiviral therapy, prognosis, HBV-DNA load
INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most frequent neoplasm worldwide and represents the third leading cause of cancer-related mortality (1). Surgical resection has been standard curative treatment for HCC patients with resectable tumors and unimpaired liver function (2). Unfortunately, tumor recurrence rate was very high after curative therapy with a 5-year recurrence rate of 70% (3). Currently, a major challenge encountered in HCC therapy is improving the prognosis of surgical patients. Hepatitis B virus (HBV) viral load is considered to be an important factor in predicting tumor recurrence (4), and high serum HBV-DNA levels seem to be associated with poor prognosis after the curative HCC resection (5). Liver resection can cause HBV reactivation in most HBV-related HCC patients, and HBV reactivation was related to tumor recurrence (6). However, although it has been extensively established that antiviral therapy can reduce the risk of tumor recurrence, antiviral therapy decreasing HBV reactivation has very rarely been studied.

In addition to these, previous studies have shown that antiviral therapy can reduce the risk of tumor recurrence in patients with high or low preoperative HBV-DNA loads (HBV-DNA < 2,000 IU/ml) (7, 8). However, some conflicting findings that antiviral therapy can improve outcomes in patients with low preoperative HBV-DNA loads have been reported. Huang et al., using a randomized controlled trial, suggested that antiviral group had better outcomes in the recurrence-free survival (RFS) and overall survival (OS) (8). Another study demonstrated that antiviral treatment showed a survival advantage for patients with low preoperative HBV-DNA loads (9). On the contrary, a cohort study observed antiviral treatment had no effects on improving postoperative RFS and OS (10).

Therefore, the purpose of this meta-analysis was to evaluate the effect of antiviral therapy on HBV reactivation and survival in patients with low preoperative HBV-DNA loads undergoing curative resection.

METHODS

Databases and Searches

The literature was searched by computer without language constraints, using PubMed, Web of Science, Embase, and the Cochrane Library until May 2020. The predefined search policies were combinations of the Medical Subject Heading terms: “Carcinoma, Hepatocellular,” “antiviral agents,” “virus activation,” “Hepatocytectomy,” “nucleotide analog,” “adefovir,” “entecavir,” “HCC,” “liver cancer,” “hepatic cancer,” “liver resection,” “surgical resection,” “radical resection,” “curative resection,” “hepatic resection,” and free text words. Through this retrieval method, 453 articles were retrieved. A manual review of the reference list of relevant articles identified four additional studies.

Study Selection

The criteria for inclusion were: (1) randomized controlled trials (RCT), prospective or retrospective cohort studies or case-control studies that enrolled HBV-related HCC patients who received curative resection as the initial treatment and their serum HBV DNA level was <2,000 IU/ml; (2) consisting of adjuvant antiviral treatment and a control arm of placebo or no treatment after liver resection; (3) no previous antiviral therapy before surgery; (4) adequate follow-up data on HBV reactivation, postoperative liver function, and OS of HCC patients.

Data Extraction and Synthesis

Two authors (KL and JH) independently extracted the following data from the published reports: first author, country of origin, year of publication, study design, study population characteristics, number of patients AVT/non-AVT, type of antiviral agent used, cut-off value of low HBV DNA level, number of patients reactivation, hazard ratio (HR) with 95% confidence interval (CI) for OS and the value of ALT (alanine aminotransferase) at the 30th day postoperatively. In the included literature, some studies included people with both high and low viral loads, and this study only included people with low viral loads in the literature. Any disagreement between them was resolved by consensus. In this study, HBV reactivation after curative resection was considered as the primary endpoint. A consensus about the definition of HBV reactivation has been reached: it is an abrupt increase in serum HBV DNA levels by at least 1 log10 from baseline or its absolute value surpasses 10^9 copies/Ml (11). OS and the value of ALT at the 30th day postoperatively served as secondary outcome. We used Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) to assess the methodological quality of non-randomized controlled studies. The risk of bias in each included RCTs was assessed by using Cochrane risk assessment tools.

Statistical Analysis

The meta-analysis was done using the Cochrane Review Manager (RevMan, version 5.3; The Cochrane Collaboration, Copenhagen, Denmark) software. Statistical analysis for dichotomous variables time-to-event variables and continuous variables were respectively carried out using relative risk (RR), hazard ratio (HR), and mean difference (MD) as the summary statistic. A fixed-effect model, the Mantel–Haenszel method, was used for homogeneous studies including dichotomous variables. Inverse variance method was used for pooling HR, MD. A value of P below 0.05 was considered statistically significant. The publication bias was evaluated by visual analysis of the funnel plots. We assessed heterogeneity by \( \chi^2 \) and \( I^2 \) statistics. A fixed-effect model was used for comparison when heterogeneity was not substantial (\( I^2 < 25\% \)).

RESULTS

Characteristics of Studies Included in Meta-Analysis

There were 453 articles identified through the systematic search and four additional manually searched articles, which comprised 449 HCC patients receiving antiviral therapy and 682 HCC patients without antiviral therapy (Figure 1). The main
characteristics of the studies assessed by meta-analysis are outlined in Table 1. The main treatment in all the included studies was surgical resection. All studies were performed in Asia, among which nine were from China (8–10, 12–16, 19), and the other one was from Republic of Korea (17). Among the reviewed studies, three were RCTs and seven were NRCTs. All included articles were published between 2012 and 2019.

The methodological features of included non-randomized controlled studies are shown in Table 2. Among the seven observational studies included in the meta-analysis, only one was judged to have a serious risk of confounding bias. The remaining six studies were deemed to have a moderate (n = 4) or low (n = 2) risk of bias. For the three randomized trials identified among the included studies, we had some concerns regarding the risk of bias in the random sequence generation and allocation hiding due to the design flaw of study (Figure 2).

**Antiviral Therapy and HBV Reactivation**
Nine of ten studies reported on HBV reactivation (Figure 3). Antiviral treatment significantly reduced the risk of HBV reactivation with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21); P < 0.00001) without statistical heterogeneity (I^2 = 0%, P = 0.97 for \( \chi^2 \)) in the meta-analysis.

**Antiviral Therapy and Overall Survival Rate**
Data were collected from three of the ten studies that reported 3-year OS. The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74); P = 0.0002) without statistical heterogeneity (I^2 = 0%, P = 0.66 for \( \chi^2 \)) in the meta-analysis (Figure 4). Due to limited data available, the effect of antiviral therapy on local tumor recurrence or disease-specific survival could not be analyzed in this study and no valid conclusions could be drawn.

**Antiviral Therapy and Liver Function**
Though antiviral therapy often shows an advantage in long-term liver function of patients; however, due to limited data, our study did not conduct long-term liver function analysis. According to the analysis of the included literature, the available and meaningful data were ALT values at 30 days postoperatively. Pooled data from four of the ten studies revealed that ALT levels were lower, but not statistically significant (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36), in patients receiving antiviral therapy. There was still no heterogeneity in this group (I^2 = 0%, P = 0.92 for \( \chi^2 \)) (Figure 5). The safety of antiviral therapy was well demonstrated, and none of the included studies provided data on adverse events associated with antiviral treatment.

**Publication Bias Analysis**
No evidence of asymmetry was identified in funnel plots of OS and ALT. However, a funnel plot for HBV reactivation revealed a mild asymmetry, suggesting that there was publication bias (Figure 6).
### TABLE 1 | Comparisons of the studies included for meta-analysis.

| Study id | Country            | No. of patients | Study type       | M/F     | Type of antiviral agent used | Cut-off value of low HBV DNA (No.) | No. of reactivation | OS (HR,95% CI) | 30days ALT | ALT |
|----------|--------------------|-----------------|------------------|---------|-----------------------------|-------------------------------------|---------------------|----------------|------------|---------|
| Chen et al. (12) | China mainland | 20/54 | prospective study | 17/3    | Entecavir                  | <500 IU/ml                          | 1/20                | N/A            | N/A        |        |
| Chen et al. (13) | China mainland | 51/154 | retrospective cohort study | 48/3   | Entecavir (93)* lamivudine(84) adefovir dipivoxil (13) telbivudine (2) | <2,000 IU/ml                      | 15/54              | N/A            | 0.641 [0.215, 1.066] | N/A    |
| Gong et al. (14) | China mainland | 66/108 | prospective study | 58/8    | Entecavir                  | <500 IU/ml                          | 2/66                | N/A            | 35.6 ± 26.1 | 45.1 ± 11.8 |
| Huang et al. (15) | China mainland | 100/100 | RCT | 87/13 | telbivudine                | <2,000 IU/ml                          | 3/100              | N/A            | N/A        |        |
| Huang et al. (16) | China mainland | 27/34 | prospectively study | N/A    | N/A                         | <1.0 × 10^3 copies/ml               | 1/27                | N/A            | N/A        |        |
| Huang et al. (17) | China mainland | 28/29 | RCT | N/A | telbivudine                | <1.0 × 10^4 copies/ml               | 1/40                | N/A            | 22 ± 8.9   | 24.8 ± 8.7 |
| Lee et al. (18) | Republic of Korea | 13/20 | retrospective cohort study | N/A    | nucleos(t)ide analog entecavir | Undetectable, <15 IU/ml              | 1/13                | N/A            | N/A        |        |
| Liu et al. (19) | China mainland | 63/102 | RCT | 43/20 | entecavir                  | <100 IU/ml                           | 2/50                | N/A            | 35.3 ± 16.1 | 37.3 ± 16.2 |
| Xu et al. (20) | China mainland | 37/37 | cohort study | 32/5   | entecavir                  | <100 IU/ml                           | 2/35                | N/A            | N/A        |        |
| Yuan et al. (21) | China mainland | 44/44 | cohort study | 32/12  | entecavir                  | <8,866 copies/ml =1,773 IU/ml        | 1/44                | N/A            | 31.8 ± 22.4 | 43.7 ± 19.2 |

Os, Overall survival; HR, Hazard Ratio; CI, Confidence Interval; ALT, Alanine aminotransferase; AVT, antiviral therapy; *The figures in brackets denote the number of patients.

### TABLE 2 | Risk of bias assessment with ROBINS-I tool.

| study id | Bias due to confounding | Bias in selection of participants in to the study | Bias in measurement of interventions | Bias due to departures from intended interventions | Bias due to missing data | Bias in measurement of outcomes | Bias in selection of the reported result | Overall Risk |
|----------|-------------------------|-------------------------------------------------|-----------------------------------|-------------------------------------------------|--------------------------|-----------------------------------|-----------------------------------|--------------|
| Chen et al. (12) | Low                     | Low                                             | Low                               | Low                                             | Low                      | Low                               | Low                               | Low          |
| Chen et al. (13) | Moderate                | Moderate                                        | Low                               | Low                                             | Low                      | Moderate                          | Moderate                          | Moderate     |
| Gong et al. (14) | Serious                 | Low                                             | Low                               | Low                                             | Low                      | Low                               | Low                               | Serious      |
| Huang et al. (15) | Low                     | Moderate                                        | Low                               | Moderate                                        | Low                      | Moderate                          | Moderate                          | Moderate     |
| Lee et al. (16) | Low                     | Low                                             | Low                               | Low                                             | Moderate                 | Low                               | Moderate                          | Moderate     |
| Xu et al. (17)  | Low                     | Low                                             | Low                               | Low                                             | Low                      | Low                               | Low                               | Low          |
| Yuan et al. (19) | Low                     | Moderate                                        | Low                               | Low                                             | Low                      | Low                               | Moderate                          | Moderate     |
DISCUSSION

It is an urgent problem for us to improve the prognosis of liver cancer patients. Previous studies have shown that for HCC patients with preoperative high HBV-DNA loads, antiviral therapy is of great significance for preventing recurrence and improving OS (20). However, there is still uncertainty as to whether there is benefit from antiviral therapy for HCC patients with low HBV DNA load. We conducted this meta-analysis to try to answer this question.

The mechanism of HBV reactivation remains unclear. Hepatic resection induced immunosuppression may increase the risk of HBV reactivation (21), which can impair liver function (4), aggravate liver cirrhosis (22), and increase the risk of HBV-related HCC recurrence (23). However, the main therapeutic mechanism of the antiviral drug was to prevent HBV replication and then reduce HBV reactivation regardless of HBV load (24, 25). Our results showed that antiviral treatment can effectively reduce HBV reactivation in HCC patients with low preoperative HBV-DNA loads undergoing curative resection. Tseng et al. revealed that HCC risk in hepatitis e antigen negative patients with low viral loads depends on HBsAg levels, not HBV DNA levels (26). Therefore, HBsAg seroclearance is considered as a safer antiviral treatment endpoint and has good off-treatment durability (27). We did not perform subgroup analysis because there was no significant heterogeneity.

Moreover, this study demonstrates that antiviral treatment is significant in improving OS rate in low viral load patients.
To strengthen the study, we restricted the meta-analysis to 3-year OS rates. All included trials have available and comparable OS rates data at that time. Though antiviral treatment has no direct antitumorous effect, it can prevent HBV reactivation, inhibit hepatitis activity, reduce inflammation in liver remnants, and reverse cirrhosis and liver dysfunction (28). The hepatitis activity in the non-tumorous liver is known to be associated with tumor recurrence after hepatectomy. Antiviral therapy can reduce HCC risks by downregulating hepatic inflammation and related nuclear signaling pathways that lead to neoplastic transformation (8). In addition, antiviral therapy can also reduce the expression of the HBx protein to levels insufficient to promote HCC development and enhance tolerance to therapy against recurrence and leads to increased OS (29).

Previous studies have revealed that antiviral therapy can significantly improve liver function in patients with HBV-related HCC (28). In the present study, there was no statistical difference in ALT level on the 30th postoperative day between antiviral groups and non-antiviral groups. During the perioperative period, surgical factors such as hepatectomy induced severe damage of liver cells, the volume of liver parenchyma resected, and clamping of hepatic vessel may play a greater role in liver function recovery. Moreover, most of patients received antiviral therapy immediately when they developed HBV reactivation, which prevented the progress of hepatitis caused by replication of virus. In fact, antiviral therapy often shows an advantage in long-term liver function of patients, especially in patients with decompensated cirrhosis (30) and the improvements became most apparent after 9 months (31). Liu et al. also revealed that the treatment group had better postoperative liver function than the control group after a 1-year follow-up (18), which suggested antiviral treatment may have the advantage in long-term prognosis.

Certain limitations must be considered when interpreting study findings. First, although we conducted an extensive literature search, only three RCTs related to this theme were included in this meta-analysis, and one of the ten studies has serious risk of bias. There is concern with lacking well-designed prospective clinical trials in the literature. More well-designed RCTs with large sample sizes of patients are required in future analysis. Second, patients were treated with variable antiviral agents, including IFN and Nucleotide Analogue, and different timing of antiviral therapy and durations also have influence on the HBV reactivation. Third, all included studies were invariably conducted in Asia. The major risk factors for HCC vary from region to region. The high HCC rates in parts of Asia largely reflect the elevated prevalence of HBV infection.
Seven genotypes (A to G) of HBV identified are associated with the disease progression and long-term outcome of HBV infection (32), and Genotypes B and C are prevalent in Asia (33). In most high risk HCC areas, such as China and South-East Asia, the key determinants are chronic HBV infection, and China alone accounting for about 50% of the total number of cases and deaths of HCC occurred worldwide (34). Therefore, it is inevitable that most HBV-related HCC studies are from Eastern countries especially from China (35). Additional studies are needed to better understand the effects of antiviral therapy on survival of HCC among other ethnic or geographic regions.

CONCLUSIONS

In conclusion, the present analysis demonstrates antiviral therapy can effectively reduce HBV reactivation and improve OS rate in patients with low viral load. Therefore, we recommend antiviral therapy for patients with HBV-associated HCC after hepatectomy without delay, regardless of the viral load.

REFERENCES

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London England) (2018) 391:1301–14. doi: 10.1016/S0140-6736(18)30010-2
2. EASL-EORTC. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 56:908–43. doi: 10.1016/j.jhep.2011.12.001
3. Ercolani G, Grazi GL, Ravaoli M, Del Gaudio M, Gardini A, Cescon M, et al. Liver reseption for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg (2003) 237:536–43. doi: 10.1097/01.sla.0000059988.22416.f2
4. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 51:890–7. doi: 10.1016/j.jhep.2009.07.009
5. Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol (2012) 38:683–91. doi: 10.1016/j.ejso.2012.04.010
6. Huang G, Lai ECH, Lau WY, Zhou W-p, Shen F, Pan Z-y, et al. Posthepatectomy HBV Reactivation in Hepatitis B-Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels. Ann Surg (2013) 257:490–505. doi: 10.1097/SLA.0b013e3182626b218
7. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg (2015) 261:56–66. doi: 10.1097/sla.0000000000000858
8. Huang G, Li PP, Lau WY, Pan ZY, Zhao LH, Wang ZG, et al. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. Ann Surg (2018) 268:943–54. doi: 10.1097/sla.0000000000002727
9. Liu XF, Zhang T, Tang K, Sui LL, Xu G, Liu Q. Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA. World J Surg Oncol (2017) 37:4701–6. doi: 10.1186/s12957-019-1577-9
10. Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: A propensity score matching analysis. World J Surg Oncol (2019) 17. doi: 10.1186/s12957-019-1577-9
11. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology (2015) 148:221–244.e223. doi: 10.1053/j.gastro.2014.10.038
12. Chen J, Bai T, Wang XB, Xie ZB, Liu JJ, Zhang Y, et al. Factors associated with postoperative HBV reactivation in HBV related hepatocellular carcinoma patients with HBV-DNA levels less than the minimum. Int J Clin Exp Med (2016) 9:4533–8.
13. Chen JL, Lin XJ, Zhou Q, Shi M, Li SP, Lao XM. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chin J Cancer (2016) 35. doi: 10.1186/s40880-016-0089-z
14. Gong WF, Zhong JH, Lu SD, Wang XB, Zhang QM, Ma L, et al. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Oncotarget (2017) 8:15047–56. doi: 10.18632/oncotarget.14789
15. Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol (Australia) (2012) 27:158–64. doi: 10.1111/j.1440-1746.2011.08888.x
16. Huang L, Li J, Yan J, Sun J, Zhang X, Wu M, et al. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat (2013) 20:336–42. doi: 10.1111/jh.12036
17. Lee JI, Kim JK, Chang HY, Lee JW, Kim JM, Chung HJ, et al. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. J Gastroenterol Hepatol (Australia) (2014) 29:1019–27. doi: 10.1111/jgh.12472
18. Liu XF, Zhang T, Tang K, Sui LL, Xu G, Liu Q. Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA. Anticancer Res (2017) 37:4701–6. doi: 10.21873/anticancer.11875
19. Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, et al. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: Analysis using propensity score matching. Oncotarget (2017) 8:51810–6. doi: 10.18632/oncotarget.15395
20. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (Chicago Ill: 1960) (2011) 146:675–81. doi: 10.1001/archsurg.2011.125
21. Xie ZB, Zhu SL, Peng YC, Chen J, Wang XB, Ma L, et al. Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Study design: K-XL, J-GH. Writing: K-XL, TL. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Taishan Scholars Program for Young Experts of Shandong Province (tsqn20161064), the National Natural Science Foundation of China (Grant No. 81874178 and 82073200).
patients with hepatitis B-related hepatocellular carcinoma. J Surg Oncol (2015) 112:634–42. doi: 10.1002/jso.24044
22. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology (2013) 58:1537–47. doi: 10.1002/hep.26301
23. Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: The Case of Hepatitis B. J Clin Oncol: Off J Am Soc Clin Oncol (2016) 34:83–90. doi: 10.1200/jco.2015.61.5724
24. Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol (2014) 8:1–9. doi: 10.1016/j.coviro.2014.04.005
25. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. Nat Microbiol (2019) 4:914–24. doi: 10.1038/s41564-019-0421-x
26. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 142:1140–1149 e1143; quiz e1113-1144. doi: 10.1053/j.gastro.2012.02.007
27. Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut (2014) 63:1325–32. doi: 10.1136/gutjnl-2013-305517
28. Luo XM, Luo G, Ye LT, Luo C, Shi M, Wang D, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver International: Off J Int Assoc Study Liver (2013) 33:595–604. doi: 10.1111/liv.12112
29. Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong I, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther (2015) 41:199–208. doi: 10.1111/apt.13034
30. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis (2006) 26:142–52. doi: 10.1055/s-2006-939752
31. Villeneuve JP, Condreay LD, Willems B, Pominer-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 31:207–10. doi: 10.1002/hep.510310130
32. Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol (2017) 31:249–55. doi: 10.1016/j.bpg.2017.04.010
33. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 2:395–403. doi: 10.1016/s1473-3099(02)00315-8
34. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65:87–108. doi: 10.3322/cac.21262
35. Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer (2013) 119:126–35. doi: 10.1002/cncr.27697

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Hong, Wu, Dong, Yang, Yan, Yan, Yao, Li, Zhi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.